Accretion Therapeutics, Inc. — SEC Form D Filing

Accretion Therapeutics, Inc. filed an SEC Form D on February 17, 2026, reporting $750K raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
February 17, 2026
Amount reported
$750K
Round stage
Series A
Industry
Pharmaceuticals
Website
https://accretionpharma.com/

What the company does

Securities: Simple Agreement for Future Equity (SAFE). Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Access to high-quality pharmaceuticals can be limited in some regions, affecting healthcare outcomes.

Solution

Accretion Pharmaceuticals manufactures safe, effective, and innovative pharmaceutical products to improve access to healthcare.

Verdict

Investors were drawn to Accretion Therapeutics at this moment because the urgency of improving access to high-quality pharmaceuticals aligned with rising healthcare demands, not because the competitive landscape seemed clear. They implicitly bet on a gap in healthcare procurement that could deliver consistent returns through innovation and quality assurance. However, the limited upside lies in the common challenge of navigating regulatory hurdles, which can stifle growth and introduce unpredictability in outcomes.

Source: SEC EDGAR Form D filing